Diagnostic Approach for Cognitive Impairment

Initial Evaluation

The American Academy of Neurology recommends beginning with brief validated cognitive screening tools, such as the Montreal Cognitive Assessment (MoCA) or Mini-Cog, followed by basic laboratory testing and brain MRI to exclude reversible causes, then proceeding to formal neuropsychological testing if screening suggests impairment 1
A validated brief cognitive assessment instrument should be used rather than relying on subjective reports alone, as recommended by the Alzheimer's Association 1, 2

Neuroimaging and Laboratory Evaluation

The American College of Radiology recommends brain MRI (non-contrast) as the preferred initial imaging modality to evaluate structural causes, including stroke, white matter disease, atrophy patterns, hydrocephalus, and space-occupying lesions, although CT scan is acceptable if MRI is contraindicated or unavailable 3
Liver function tests (ALT, AST) are particularly important, as hepatic encephalopathy can present with attention deficits and forgetfulness, according to the European Association for the Study of the Liver 3

Formal Neuropsychological Testing

If screening tests suggest impairment, the National Institute of Neurological Disorders and Stroke recommends proceeding to comprehensive neuropsychological assessment focusing on attention and memory domains 1, 4
Attention lapses are strongly correlated with memory failures and should be systematically evaluated using tests such as the five-choice serial reaction time task (5-CSRTT) for sustained attention, as suggested by the Alzheimer's Association 5

Clinical Considerations

The American Academy of Neurology advises against dismissing subjective forgetfulness as "normal aging" without objective assessment, as changes that may be common with advancing age are not always normal and warrant diagnostic evaluation 2
The Alzheimer's Association recommends recognizing that forgetfulness is non-specific and can be related to anxiety, depression, and somatic symptoms, rather than dementia alone 2
Interviewing both patient and informant separately when possible is valuable, as diminished insight is common in cognitive impairment, and divergent perspectives between patient and care partner provide valuable diagnostic clues, according to the American Psychiatric Association 2

Laboratory Evaluation for Poor Memory

Initial Laboratory Panel (Tier 1)

The American College of Physicians recommends a comprehensive metabolic panel, complete blood count, thyroid-stimulating hormone (TSH), vitamin B12, and liver function tests as first-line laboratory screening for patients presenting with poor memory, complemented by brain neuroimaging (preferably MRI) 6
Liver function tests (ALT, AST) are recommended for hepatic encephalopathy assessment in patients with poor memory 6, 7
Hemoglobin A1c (HbA1c) is recommended to evaluate diabetes control in patients with poor memory 6, 7

Neuroimaging (Tier 1)

Brain MRI (non-contrast) is the preferred initial imaging modality to evaluate for structural causes including stroke, white matter disease, atrophy patterns, hydrocephalus, and space-occupying lesions in patients with poor memory 6, 7
CT scan is acceptable if MRI is contraindicated or unavailable, with coronal reformations recommended to assess hippocampal atrophy in patients with poor memory 6, 7

Additional Testing Based on Clinical Context (Tier 2)

Lipid panel is recommended for vascular risk stratification in patients with poor memory 6, 7

Specialized Testing (Tier 3-4)

Lumbar puncture with CSF analysis is recommended for early-onset dementia (<65 years), rapidly progressive dementia, or when autoimmune/infectious/paraneoplastic causes are suspected in patients with poor memory 6, 8
Blood biomarkers for amyloid pathology are emerging tools that may reduce need for CSF or PET imaging in appropriate clinical contexts (patients with objective cognitive impairment where AD is suspected after comprehensive workup) 9

Critical Clinical Considerations

Cognitive testing, such as validated instruments like the MoCA or MMSE, should accompany laboratory evaluation to establish objective cognitive impairment in patients with poor memory 10, 11
For hepatic encephalopathy specifically, blood ammonia levels may be helpful but hyperammonemia can occur without encephalopathy, and clinical assessment remains paramount 8

Laboratory Testing for Decreased Cognition

Mandatory Tier 1 Laboratory Tests

The American Academy of Neurology recommends that all patients presenting with decreased cognition should undergo routine Tier 1 laboratory testing including complete blood count, comprehensive metabolic panel, thyroid-stimulating hormone (TSH), and vitamin B12 levels, with additional testing individualized based on clinical presentation and risk factors 12
Complete blood count (CBC) screens for anemia and infection in all patients presenting with cognitive impairment to identify potentially reversible causes 12
Comprehensive metabolic panel evaluates electrolyte disturbances, renal function, glucose abnormalities, and hepatic function in all patients presenting with cognitive impairment to identify potentially reversible causes 12
Thyroid-stimulating hormone (TSH) with free T4 if abnormal, is used to diagnose hypothyroidism, a common reversible cause of cognitive impairment 12
Vitamin B12 and folate levels are tested to identify deficiency, which can cause dementia that substantially improves with treatment 12

Tier 3-4 Specialized Testing (Selected Cases Only)

The Alzheimer's Association recommends CSF Alzheimer's biomarkers (Aβ42/Aβ40 ratio, p-tau181, t-tau) for patients with mild dementia to identify or exclude AD as the underlying cause, with a strong recommendation 13
Blood biomarkers for amyloid pathology are emerging tools that may reduce the need for CSF or PET imaging in appropriate clinical contexts, such as patients with objective cognitive impairment where AD is suspected after comprehensive workup 14

Critical Accompanying Assessments

Validated cognitive testing (MoCA, Mini-Cog, or MMSE) is necessary to establish objective cognitive impairment, as laboratory results alone are insufficient, according to the American Academy of Neurology 12, 15
Structural brain imaging (MRI preferred over CT) is used to evaluate for stroke, white matter disease, atrophy patterns, hydrocephalus, and space-occupying lesions, and should be paired with laboratory testing 12

Diagnostic Evaluation of Cognitive Impairment

Rationale for Neuroimaging

The 5th Canadian Consensus Conference on Dementia recommends anatomical neuroimaging for patients with significant cognitive impairment, such as a MoCA score of 17/30, to exclude reversible causes and characterize underlying pathology 16
A MoCA score of 17/30 represents moderate-to-severe cognitive impairment, indicating the need for investigation of underlying etiology 16

MRI as the Preferred Modality

The American College of Radiology recommends MRI over CT for dementia evaluation due to its superior sensitivity for detecting vascular lesions, hippocampal atrophy, and subtle structural abnormalities 16, 17, 18
MRI is preferred for detecting vascular contributions, such as white matter hyperintensities and lacunar infarcts, as well as neurodegenerative patterns, including hippocampal atrophy and posterior cortical atrophy 17, 18, 19

Critical Diagnostic Considerations

The American College of Radiology suggests that 3T MRI should be favored over 1.5T if available and no contraindications exist 16
Early-onset cognitive impairment, such as in a 57-year-old patient, has different diagnostic implications, including a higher likelihood of atypical or non-Alzheimer's pathology, and a greater need to exclude structural lesions 16, 19, 20
Neuroimaging will help determine vascular contributions, neurodegenerative patterns, structural lesions, and inflammatory/infectious processes 16, 17, 18, 19

Complementary Laboratory Evaluation

The Metabolism: Clinical and Experimental journal recommends concurrent laboratory testing, including hemoglobin A1c, to evaluate for potential underlying causes of cognitive impairment 21